CJC-1295 With DAC — Spray

Scientific identity

CJC-1295 with DAC (CAS 446262-90-4; PubChem CID 56841945), formally designated Nε30-maleimidopropionyl-[D-Ala², Gln⁸, Ala¹⁵, Leu²⁷]-Sermorelin-Lys30, is a synthetic 30-residue albumin-binding GHRH analogue. Molecular formula C₁₆₅H₂₆₉N₄₇O₄₆; molecular weight approximately 3,647.25 g/mol.

Compound class

Synthetic 30-residue modified GHRH analogue; long-acting GHRHR agonist via albumin conjugation; investigational research compound. Classified as a Research Use Only material and is not a drug, dietary supplement, food, or cosmetic.

Structural features

The compound incorporates the same four amino acid substitutions as CJC-1295 without DAC — D-Ala², Gln⁸, Ala¹⁵, Leu²⁷ — conferring resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage at the native Tyr-Ala N-terminal bond. It additionally carries a C-terminal lysine extended with an N-maleimidopropionamide linker (the DAC modification) that selectively reacts with the free thiol of Cys34 on serum albumin under physiological conditions, forming a covalent thioether bond. The resulting albumin conjugate is subject to neonatal Fc receptor (FcRn)-mediated recycling, reducing renal clearance and extending circulating residence time.

Distinction from CJC-1295 without DAC

CJC-1295 with DAC (CAS 446262-90-4, ~3,647 g/mol, 30 residues) differs from CJC-1295 without DAC (CAS 446036-97-1, ~3,368 g/mol, 29 residues) by approximately 279 Da — a mass difference readily confirmed by mass spectrometry. Their functional half-lives differ substantially: approximately 6–8 days for the DAC form versus approximately 30 minutes for the non-DAC form. These pharmacokinetic differences make the two forms appropriate for different experimental contexts — sustained tonic GHRHR engagement versus pulsatile short-duration receptor stimulation — and evidence from one should not be attributed to the other.

Primary molecular target

GHRHR (growth hormone-releasing hormone receptor) — a Class B Gαs-coupled GPCR expressed predominantly on pituitary somatotroph cells.

Product content

5mg per bottle; 45 sprays per bottle. Per-spray quantity is documented on the product label and batch Certificate of Analysis.

Physical form. Liquid research spray.

Purity: Research-grade.

Analytical documentation

A batch-specific Certificate of Analysis is available on the Longevia Research website, covering compound identity, purity, and lot traceability. Mass spectrometric confirmation of the molecular weight (~3,647 g/mol) simultaneously confirms the DAC-containing form and distinguishes it from the non-DAC analogue.

Research-use classification

Research Use Only. Not approved for human or veterinary use. Not intended for administration to humans or animals.

GHRH biology and CJC-1295 with DAC pharmacological background

GHRH is a 44-amino-acid hypothalamic neuropeptide and the primary stimulatory regulator of GH secretion from anterior pituitary somatotrophs, released in episodic pulses from hypothalamic arcuate nucleus neurons and acting via GHRHR — a Class B GPCR that couples to Gs and stimulates adenylyl cyclase, increasing intracellular cAMP and driving both acute GH release and longer-term transcriptional regulation of GH gene expression. Native GHRH is rapidly inactivated in circulation — functional half-life approximately 7 minutes — by DPP-IV cleavage at the Tyr-Ala N-terminal bond. CJC-1295 with DAC addressed two distinct limitations of native GHRH: the four amino acid substitutions confer DPP-IV resistance by modifying the scissile N-terminal dipeptide, and the C-terminal DAC modification then extends functional residence time by enabling albumin conjugation. In-vitro receptor pharmacology work established that CJC-1295 with DAC retains full agonist activity at GHRHR, activating cAMP-mediated intracellular signaling consistent with native GHRH — confirming that the structural modifications preserve receptor engagement. This foundational characterization was published by Jette and colleagues (Endocrinology, 2005; PMID 15817669).

Published pharmacokinetic and pharmacodynamic research

The principal published pharmacokinetic and pharmacodynamic characterization of CJC-1295 with DAC is from Teichman and colleagues (Journal of Clinical Endocrinology and Metabolism, 2006; PMID 16352683), who conducted a dose-escalation study administering the compound as a single subcutaneous injection to healthy adult volunteers across multiple dose cohorts. The study reported a mean terminal half-life in the range of 5.8–8.1 days across cohorts, consistent with the albumin-conjugation mechanism. GH pulses and mean IGF-1 levels were measured as pharmacodynamic markers over the observation period; these are pharmacodynamic observations from a specific clinical pharmacology protocol characterizing the compound's investigational behavior in that study population, not evidence of therapeutic efficacy for any indication. Jette and colleagues' 2005 rat model pharmacokinetic studies provided the preclinical foundation, demonstrating substantially extended plasma half-lives for GH-releasing factor albumin bioconjugates compared with unconjugated GRF(1-29) analogues.

Key research areas and preclinical context

Alba and colleagues (American Journal of Physiology — Endocrinology and Metabolism, 2006; PMID 16849629) examined once-daily CJC-1295 administration in GHRH knockout mice — a model of GH deficiency caused by absence of functional endogenous GHRH — reporting association with normalization of growth parameters relative to untreated knockout controls. This is a rodent model study in a specific GH-deficient experimental system; findings cannot be generalized to human physiology. Ionescu and Frohman (JCEM, 2006) examined the physiological significance of pulsatile GH release and the experimental implications of long-acting versus short-acting GHRH analogue tools — a conceptual framing relevant to researchers choosing between the DAC and non-DAC forms for experimental design. Researchers selecting CJC-1295 with DAC versus without DAC are effectively choosing between sustained tonic GHRHR engagement and pulsatile short-duration receptor stimulation as experimental paradigms.

Regulatory status

CJC-1295 with DAC has been examined in human pharmacokinetic studies as an investigational compound under development by ConjuChem Biotechnologies. No regulatory authority has approved CJC-1295 with DAC for any human therapeutic indication, and no marketing approval exists in any jurisdiction. The compound is listed on the World Anti-Doping Agency (WADA) Prohibited List under category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a GH-releasing factor, prohibited at all times for athletes subject to WADA oversight. Longevia Research supplies this compound for laboratory research use only, independent of pharmaceutical development or therapeutic access pathways.

For a 30-residue albumin-reactive peptide such as CJC-1295 with DAC, analytical quality documentation carries particular importance. The maleimide moiety on the DAC modification is reactive — it is designed to conjugate to albumin under physiological conditions — and its integrity in stored research material requires verification. Unreacted maleimide, hydrolysed maleamide (the ring-opened form), and unconjugated precursor peptide all represent analytically distinct entities that should be distinguishable in quality documentation.

Identity confirmation: Each production lot of Longevia's CJC-1295 with DAC spray is characterised by mass spectrometric analysis, verifying the observed molecular ion against the expected mass for the intact 30-residue DAC-modified peptide at approximately 3,647.25 g/mol (C₁₆₅H₂₆₉N₄₇O₄₆). This molecular weight is approximately 279 Da heavier than the No DAC variant (~3,368 g/mol) — a difference that is readily resolved by mass spectrometry and serves as the definitive identification of the DAC modification's presence.

Purity assessment: Chromatographic purity analysis quantifies the target compound relative to all UV-absorbing species in the chromatogram. For CJC-1295 with DAC, this includes monitoring for hydrolysis products of the maleimide group (ring-opened maleamide) and the underlying peptide backbone — both analytically distinguishable from the intact compound.

Batch traceability and Certificate of Analysis: Every production lot of CJC-1295 with DAC 5mg spray is traceable to a specific batch. A batch-specific Certificate of Analysis is accessible on the Longevia Research website, covering compound identity, purity, and lot information. Researchers are strongly encouraged to review the batch documentation — particularly the molecular weight confirmation — before use.

Storage: Specific storage conditions for this lot are confirmed on the batch Certificate of Analysis and product labelling. The reactive maleimide moiety in CJC-1295 with DAC requires protection from thiol-containing reagents and conditions that accelerate hydrolysis; researchers should follow the COA's lot-specific guidance and avoid mixing the compound with materials containing free thiols in laboratory handling.

Longevia Research supplies CJC-1295 with DAC 5mg Spray for laboratory and in-vitro research use only. The product is intended for qualified researchers and trained laboratory personnel working in appropriate controlled research environments.

CJC-1295 with DAC is a synthetic research peptide supplied strictly as a laboratory research tool. It is not a drug, not a dietary supplement, not a food or food ingredient, and not a cosmetic. No regulatory authority has approved CJC-1295 with DAC for any human or veterinary therapeutic use. The compound is listed on the WADA Prohibited List and is prohibited for athletes subject to anti-doping oversight.

This product must not be confused with CJC-1295 without DAC (Modified GRF 1-29, CAS 446036-97-1) — a structurally distinct compound with a different molecular weight, different CAS number, and different pharmacokinetic profile.

No therapeutic, diagnostic, or efficacy claims are made for this compound. The pharmacokinetic and pharmacodynamic findings referenced on this page describe results from specific clinical pharmacology protocols involving the investigational compound; they do not establish that the Longevia research material is safe, effective, or approved for any human application. No dosing instructions, spray-frequency guidance, administration protocols, or cycle recommendations are provided. The purchaser assumes full responsibility for lawful acquisition, handling, storage, use, and disposal of this material, and for compliance with all applicable local, state, federal, and institutional regulations.